Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Post-Marketing Adverse Events of Oncology Medications with Breakthrough Therapy Designation Correlated with Time on Market and Market Share

Speaker(s)

Heitlage V1, Farley JF2, Shah R3, Tyagi H3, Stenehjem D4
1University of Minnesota, College of Pharmacy, Port Orange, FL, USA, 2University of Minnesota, College of Pharmacy, Minneapolis, MN, USA, 3University of Minnesota, Minneapolis, MN, USA, 4University of Minnesota, Duluth, MN, USA

Presentation Documents

Objectives: Breakthrough Therapy Designation (BTD) is an expedited drug pathway frequently used to bring oncology drugs to market. Historically, oncology drugs have high rates of adverse events (AEs). In this study, we compare post-marketing adverse events (PMAEs) in oncology medications approved with BTD vs. without BTD.

Methods: Data on all new drug applications (NDAs) 2012-2019 from the Drugs@FDA database was combined with PMAEs from the FDA Adverse Event Reporting System (FAERS) database. FAERS data reports PMAEs per year as the number of AEs divided by the duration of time the drug was on the market. Market share was estimated using publicly reported drug company earnings in 2019, and further categorized as high (n=7), medium (n=36), and low (n=49). Statistical comparisons were made using chi squared (X2), ANOVA, and logistical regression tests.

Results: Among the 92 oncology NDAs approved between 2012 and 2018, 36 (39%) received a BTD while 56 (61%) did not. Logistical regression and X2 testing reveal no statistically significant differences in BTD by drug class, date of release, and number of PMAEs reported per year on market. However, when including duration on the market as a covariate, BTD association with PMAEs became significant. An ANOVA model with BTD, time on market, and market share effect on total PMAEs revealed a significant main effect model F (4,85) = 13.7, p <0.0001 and a significant interaction with BTD, F (1,2) = 5.18, p < 0.25 and high market share F (1,2) = 23.7, p= <0.0001. This indicates that BTD and high market share is associated with total PMAEs.

Conclusions: Oncology medications with BTD and high market share are associated with total PMAEs. BTD significance appears to be suppressed in statistical models when time on market is omitted.

Code

EPH138

Topic

Clinical Outcomes, Epidemiology & Public Health, Health Policy & Regulatory, Real World Data & Information Systems

Topic Subcategory

Approval & Labeling, Clinical Outcomes Assessment, Distributed Data & Research Networks, Safety & Pharmacoepidemiology

Disease

Drugs, Oncology